{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "currency": "EUR", "market": "dr_market", "esgPopulated": false, "gmtOffSetMilliseconds": 7200000, "exchange": "FRA", "longName": "CytomX Therapeutics, Inc.", "shortName": "CYTOMX THERAPEUTICS INC.", "regularMarketPrice": 1.592, "regularMarketChangePercent": -3.1630197, "messageBoardId": "finmb_60504284", "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.45460773, "fiftyTwoWeekLow": 1.118, "fiftyTwoWeekHigh": 2.919, "earningsTimestamp": 1683666000, "earningsTimestampStart": 1690973940, "earningsTimestampEnd": 1691409600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 0.47399998, "fiftyTwoWeekLowChangePercent": 0.42397135, "fiftyTwoWeekRange": "1.118 - 2.919", "fiftyTwoWeekHighChange": -1.3269999, "epsTrailingTwelveMonths": -1.37, "epsForward": -1.54, "epsCurrentYear": -1.15, "priceEpsCurrentYear": -1.3843479, "sharesOutstanding": 66338900, "bookValue": -1.295, "fiftyDayAverage": 1.63682, "fiftyDayAverageChange": -0.04481995, "fiftyDayAverageChangePercent": -0.027382335, "twoHundredDayAverage": 1.6855325, "twoHundredDayAverageChange": -0.09353244, "twoHundredDayAverageChangePercent": -0.055491332, "marketCap": 108016720, "forwardPE": -1.0337663, "priceToBook": -1.2293437, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1446188400000, "priceHint": 4, "regularMarketChange": -0.052000046, "regularMarketTime": 1683871215, "regularMarketDayHigh": 1.592, "regularMarketDayRange": "1.592 - 1.592", "regularMarketDayLow": 1.592, "regularMarketVolume": 900, "regularMarketPreviousClose": 1.644, "bid": 1.64, "ask": 1.666, "bidSize": 2000, "askSize": 2000, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 1.592, "averageDailyVolume3Month": 1081, "averageDailyVolume10Day": 830, "symbol": "6C1.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "151 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 515 3185", "fax": "650 351 0353", "website": "https://www.cytomx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 116, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sean A. McCarthy D.Phil., DPHIL", "age": 55, "title": "Chairman & CEO", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 1025446, "fmt": "1.03M", "longFmt": "1,025,446"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4289, "fmt": "4.29k", "longFmt": "4,289"}}, {"maxAge": 1, "name": "Mr. Lloyd A. Rowland Jr., J.D.", "age": 65, "title": "Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.", "yearBorn": 1957, "fiscalYear": 2022, "totalPay": {"raw": 608718, "fmt": "608.72k", "longFmt": "608,718"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 150, "fmt": "150", "longFmt": "150"}}, {"maxAge": 1, "name": "Mr. Jeffrey  Landau B.S., M.B.A.", "age": 44, "title": "Sr. VP, Head of Strategy & Chief Bus. Officer", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": {"raw": 581683, "fmt": "581.68k", "longFmt": "581,683"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 150, "fmt": "150", "longFmt": "150"}}, {"maxAge": 1, "name": "Mr. Christopher W. Ogden", "age": 38, "title": "Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer", "yearBorn": 1984, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marcia P. Belvin Ph.D.", "title": "Sr. VP & Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Chau  Cheng M.B.A., Ph.D.", "title": "VP of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Danielle  Olander-Moghadassian", "title": "Sr. VP & Chief HR Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Leslie  Robbins", "title": "Sr. VP of Intellectual Property", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hoyoung  Huh M.D., Ph.D.", "age": 53, "title": "Special Advisor to Chief Exec. Officer", "yearBorn": 1969, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 3, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}